Clinical Scorecard: Choosing the Best Strategy for Evaluating Hypertension-Related Organ Damage: A Tailored Perspective
At a Glance
Category
Detail
Condition
Hypertension-mediated organ damage (HMOD)
Key Mechanisms
Chronic elevated blood pressure causes structural and functional changes in small and large arteries and end-organs (heart, kidneys, eyes, brain), influenced by genetics, age, sex, and comorbidities
Target Population
Patients with arterial hypertension, especially those with additional cardiovascular risk factors or comorbidities
Care Setting
Primary and specialized healthcare settings
Key Highlights
Basic HMOD assessment (ECG, serum creatinine, eGFR, urinary albumin-creatinine ratio) is recommended in all hypertensive patients.
Advanced HMOD tests (echocardiography, arterial stiffness measurement, imaging) are indicated selectively based on initial findings and potential to change management.
Presence of HMOD increases cardiovascular risk 2–3-fold and guides initiation and intensification of blood pressure-lowering treatment.
Guideline-Based Recommendations
Diagnosis
Perform basic HMOD screening in all patients with hypertension using ECG, serum creatinine with eGFR, and urinary albumin-creatinine ratio.
Use echocardiography as the preferred initial advanced test to detect cardiac HMOD and add prognostic information.
Consider ultrasound, coronary artery calcium scoring, or pulse wave velocity in young/middle-aged patients or those near treatment thresholds if results will influence management.
Management
Initiate antihypertensive treatment in all patients with BP ≥140/90 mmHg, preferably with ACEi/ARB combined with thiazide or calcium channel blocker.
Use presence of HMOD to guide treatment initiation in patients with BP 130–139/80–89 mmHg who otherwise might not be treated.
Tailor advanced diagnostic testing to patients where findings will alter clinical management.
Monitoring & Follow-up
Regularly assess cardiac and renal function through ECG and laboratory tests in hypertensive patients.
Repeat advanced imaging or arterial stiffness measurements as clinically indicated based on initial findings and treatment response.
Risks
HMOD presence indicates a 2–3-fold increased risk of cardiovascular disease morbidity and mortality.
Patients with clustering of risk factors such as obesity, diabetes, and renal dysfunction have higher susceptibility to HMOD.
Patient & Prescribing Data
Individuals with arterial hypertension, especially those with additional cardiovascular risk factors or borderline blood pressure levels
Detection of HMOD supports initiation or intensification of blood pressure-lowering therapy, particularly in patients with BP near treatment thresholds who may otherwise not receive treatment.
Clinical Best Practices
Perform basic HMOD screening in all hypertensive patients to identify high cardiovascular risk.
Use echocardiography as the preferred advanced diagnostic tool for cardiac HMOD assessment.
Select advanced diagnostic tests based on initial assessment findings, likelihood to change management, and resource availability.
Integrate HMOD findings into cardiovascular risk stratification to guide treatment decisions.
Consider patient-specific factors such as age, sex, genetics, and comorbidities when evaluating HMOD.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
